ClinicalTrials.gg
CompletedNCT00500149Updated Jun 14, 2021Results posted

A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)

A Phase 3 interventional study of Vyvanse (lisdexamfetamine dimesylate) and Placebo in ADHD, sponsored by Shire. Completed at 9 sites in United States. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2021-06-14.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
6 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity — 1 open to participants now, 1 under way, none of them phase 3. lisdexamfetamine · Attention Deficit Disorder with Hyperactivity.

Enrollment
18th of 51
129 · median 48
Started
2007
with 2 others
Phase 3
15 of 51
none open now
Registered
5th of 51
by date
Lead sponsor
18 of 51
Shire

Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, this one is the 18th largest by enrollment, is one of 3 that started in 2007, is one of 15 in phase 3, and was the 5th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

1 of the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About lisdexamfetamine

lisdexamfetamine: first FDA approval 2007 (VYVANSE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 6 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, or all of them as a file.
02

Study summary

The primary objective of this study is to assess the time of onset of Vyvanse compared to placebo, in the analog classroom as measured by the Swanson, Kotkin, Agler, M. Flynn and Pelham (SKAMP) deportment scale in children (aged 6-12) diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD).

03

Conditions studied

04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is a male or female aged 6-12 years inclusive at the time of consent.
  2. Females of (FOCP) must have a negative serum beta Human Chorionic Gonadotropin (HCG) pregnancy test at Screening and a negative urine pregnancy test at Baseline and agree to comply with any applicable requirements of the protocol.
  3. Primary diagnosis of ADHD: combined sub-type or predominantly hyperactive impulsive sub-type based on a detailed psychiatric evaluation.
  4. Subject has a baseline ADHD-RS-IV score ≥ 28.
  5. Intelligent Quotient (IQ) score of 80 or above on the Kaufman Brief Intelligence Test (KBIT).
  6. Subject must be able to complete at least the Basic Test of the PERMP assessment.

Exclusion criteria

Exclusion Criteria:

  1. Subject has a current, controlled (requiring a restricted medication) or uncontrolled, comorbid psychiatric diagnosis with significant symptoms such as Post Traumatic Stress Disorder (PTSD), psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder
  2. Subject has Conduct Disorder.
  3. Subject has a documented allergy, or intolerance to amphetamines.
  4. Subject has failed to respond to one or more adequate courses (dose and duration) of amphetamine therapy.
  5. The subject has a recent history (within the past 6 months) of suspected substance abuse or dependence disorder (excluding nicotine) in accordance with criteria.
  6. Subject weighs less than 50 pounds (22.7kg).
  7. Subject is significantly overweight
  8. Subject had a history of seizures during the last two years (exclusive of febrile seizures), a tic disorder, a current diagnosis and/or family history of Tourette's Disorder.
  9. Subject has any reported history of abnormal thyroid function.
  10. Subject has taken another drug or taken part in a clinical trial within the last 30 days prior to Screening.
  11. Subject has a known history of structural cardiac abnormality, as well as any other condition(s) that may affect cardiac performance.
  12. Subject has a concurrent chronic or acute illness (such as severe allergic rhinitis or an infectious process requiring antibiotics), disability, or other condition that might confound the results of safety assessments
  13. Subject is taking other medications that have central nervous system (CNS) effects or affect performance, such as sedating antihistamines and decongestant sympathomimetics (bronchodilators are not exclusionary).
  14. The female subject is pregnant or lactating.
  15. Subject is well controlled on their current ADHD medication with acceptable tolerability.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
129 participants (actual)

Study arms

  • Experimental
    1

    Drug: Vyvanse (lisdexamfetamine dimesylate)

  • Placebo comparator
    2

    Drug: Placebo

Interventions

  • Following completion of the open-label dose optimization period and successful titration to an optimal dose of Vyvanse™, subjects will take their optimized dose of Vyvanse™ (30, 50 or 70 mg/day).

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Onset of Effect of Vyvanse

    The onset of effect will be defined as the first assessment time showing statistical significance between Vyvanse and placebo as measured by the Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Deportment scale. The degree of impairment is rated from 0 (normal) to 6 (maximal).

    Time frame: Evaluations were conducted at 1.5, 2.5, 5.0, 7.5, 10.0, 12.0, and 13.0 hours post-dose.

Secondary outcomes

  1. Duration of Effect of Vyvanse

    Duration of effect will be defined as the first time point at which there is a non-significant difference between Vyvanse and placebo after a time point at which there is a significant difference between the two treatment groups as measured by SKAMP Deportment Scores. The degree of impairment is rated from 0 (normal) to 6 (maximal).

    Time frame: Evaluations were conducted at 1.5, 2.5, 5.0, 7.5, 10.0, 12.0, and 13.0 hours post-dose.

07

Results

Posted Jun 5, 2009

Participant flow

129 subjects were enrolled for dose optimization phase, 12 discontinued, and 117 were randomized to the cross-over phase.

Enrolled (Dose-optimization Phase)
Participant flow — Enrolled (Dose-optimization Phase)
MilestoneVyvanse FirstPlacebo First
Started1290
Completed1170
Not completed120
Withdrew: Withdrawal by subject30
Withdrew: Adverse event80
Withdrew: Protocol violation10
First Intervention (Cross-over Phase)
Participant flow — First Intervention (Cross-over Phase)
MilestoneVyvanse FirstPlacebo First
Started5859
Completed5657
Not completed22
Withdrew: Adverse event01
Withdrew: Withdrawal by subject11
Withdrew: Protocol violation10
Second Intervention (Cross-over Phase)
Participant flow — Second Intervention (Cross-over Phase)
MilestoneVyvanse FirstPlacebo First
Started5657
Completed5457
Not completed20
Withdrew: Lost to follow-up20

Outcome measures

PrimaryOnset of Effect of Vyvanse

The onset of effect will be defined as the first assessment time showing statistical significance between Vyvanse and placebo as measured by the Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Deportment scale. The degree of impairment is rated from 0 (normal) to 6 (maximal).

Time frame:
Evaluations were conducted at 1.5, 2.5, 5.0, 7.5, 10.0, 12.0, and 13.0 hours post-dose.
Reported as:
Least squares mean · scores on a scale
Onset of Effect of Vyvanse
scores on a scaleVyvansePlacebo
1.5 hours0.70 ± 0.091.14 ± 0.09
2.5 hours0.45 ± 0.091.42 ± 0.09
5 hours0.44 ± 0.101.60 ± 0.10
7.5 hours0.54 ± 0.091.56 ± 0.09
10 hours0.60 ± 0.091.43 ± 0.09
12 hours0.90 ± 0.101.41 ± 0.10
13 hours1.05 ± 0.101.31 ± 0.10
Statistical analysis
  • Vyvanse vs Placebo · ANCOVA · p = <0.0001 (The primary efficacy variable will be onset of effect, which will be determined from the results of inferential analyses across multiple time points. No adjustment will be made to the levels of significance as a result of the multiple comparisons.)Using a linear mixed model that includes sequence, period, and treatment group as fixed effects and subject-within-sequence as a random effect.
  • Vyvanse vs Placebo · ANCOVA · p = <0.0001 (The primary efficacy variable will be onset of effect, which will be determined from the results of inferential analyses across multiple time points. No adjustment will be made to the levels of significance as a result of the multiple comparisons.)Using a linear mixed model that includes sequence, period, and treatment group as fixed effects and subject-within-sequence as a random effect.
  • Vyvanse vs Placebo · ANCOVA · p = <0.0001 (The primary efficacy variable will be onset of effect, which will be determined from the results of inferential analyses across multiple time points. No adjustment will be made to the levels of significance as a result of the multiple comparisons.)Using a linear mixed model that includes sequence, period, and treatment group as fixed effects and subject-within-sequence as a random effect.
  • Vyvanse vs Placebo · ANCOVA · p = <0.0001 (The primary efficacy variable will be onset of effect, which will be determined from the results of inferential analyses across multiple time points. No adjustment will be made to the levels of significance as a result of the multiple comparisons.)Using a linear mixed model that includes sequence, period, and treatment group as fixed effects and subject-within-sequence as a random effect.
  • Vyvanse vs Placebo · ANCOVA · p = <0.0001 (The primary efficacy variable will be onset of effect, which will be determined from the results of inferential analyses across multiple time points. No adjustment will be made to the levels of significance as a result of the multiple comparisons.)Using a linear mixed model that includes sequence, period, and treatment group as fixed effects and subject-within-sequence as a random effect.
  • Vyvanse vs Placebo · ANCOVA · p = <0.0001 (The primary efficacy variable will be onset of effect, which will be determined from the results of inferential analyses across multiple time points. No adjustment will be made to the levels of significance as a result of the multiple comparisons.)Using a linear mixed model that includes sequence, period, and treatment group as fixed effects and subject-within-sequence as a random effect.
  • Vyvanse vs Placebo · ANCOVA · p = <0.0001 (The primary efficacy variable will be onset of effect, which will be determined from the results of inferential analyses across multiple time points. No adjustment will be made to the levels of significance as a result of the multiple comparisons.)Using a linear mixed model that includes sequence, period, and treatment group as fixed effects and subject-within-sequence as a random effect.
SecondaryDuration of Effect of Vyvanse

Duration of effect will be defined as the first time point at which there is a non-significant difference between Vyvanse and placebo after a time point at which there is a significant difference between the two treatment groups as measured by SKAMP Deportment Scores. The degree of impairment is rated from 0 (normal) to 6 (maximal).

Time frame:
Evaluations were conducted at 1.5, 2.5, 5.0, 7.5, 10.0, 12.0, and 13.0 hours post-dose.
Reported as:
Least squares mean · scores on a scale
Duration of Effect of Vyvanse
scores on a scaleVyvansePlacebo
1.5 hours0.70 ± 0.091.14 ± 0.09
2.5 hours0.45 ± 0.091.42 ± 0.09
5 hours0.44 ± 0.101.60 ± 0.10
7.5 hours0.54 ± 0.091.56 ± 0.09
10 hours0.60 ± 0.091.43 ± 0.09
12 hours0.90 ± 0.101.41 ± 0.10
13 hours1.05 ± 0.101.31 ± 0.10
Statistical analysis
  • Vyvanse vs Placebo · ANCOVA · p = < 0.0001Using a linear mixed model that includes sequence, period, and treatment group as fixed effects and subject-within-sequence as a random effect.
  • Vyvanse vs Placebo · ANCOVA · p = <0.0001Using a linear mixed model that includes sequence, period, and treatment group as fixed effects and subject-within-sequence as a random effect.
  • Vyvanse vs Placebo · ANCOVA · p = <0.0001Using a linear mixed model that includes sequence, period, and treatment group as fixed effects and subject-within-sequence as a random effect.
  • Vyvanse vs Placebo · ANCOVA · p = <0.0001Using a linear mixed model that includes sequence, period, and treatment group as fixed effects and subject-within-sequence as a random effect.
  • Vyvanse vs Placebo · ANCOVA · p = <0.0001Using a linear mixed model that includes sequence, period, and treatment group as fixed effects and subject-within-sequence as a random effect.
  • Vyvanse vs Placebo · ANCOVA · p = <0.001Using a linear mixed model that includes sequence, period, and treatment group as fixed effects and subject-within-sequence as a random effect.
  • Vyvanse vs Placebo · ANCOVA · p = <0.0001Using a linear mixed model that includes sequence, period, and treatment group as fixed effects and subject-within-sequence as a random effect.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vyvanse—0/115 (0%)13/115 (11.3%)
Placebo—0/115 (0%)3/115 (2.6%)
Most frequent other events
Most frequent other events
EventVyvansePlacebo
Decreased AppetiteMetabolism and nutrition disorders7/1151/115
HeadacheNervous system disorders6/1152/115

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Entire Study Population
<=18 years129
Between 18 and 65 years0
>=65 years0
Age, Continuous
Age, Continuous(years)Entire Study Population
Mean10.1 ± 1.5
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female31
Male98
Region of Enrollment
Region of Enrollment(Participants)Entire Study Population
United States129
08

Study locations

9 sites
  • Clinical Study Centers, LLC
    Little Rock, Arkansas, United States
  • Univ. of CA, Irvine Child Development Center
    Irvine, California, United States
  • Shire Clinical Research Site
    Wildomar, California, United States
  • Vince and Associates Clinical Research
    Overland Park, Kansas, United States
  • Center for Psychiatry & Behavioral Medicine Inc
    Las Vegas, Nevada, United States
  • Duke Child & Family Study Center
    Durham, North Carolina, United States
  • Duke University Medical Center
    Durham, North Carolina, United States
  • Shire Clinical Research Site
    Houston, Texas, United States
  • Shire Clinical Research Site
    Lubbock, Texas, United States
09

References and documents

Publications

  • Wigal SB, Kollins SH, Childress AC, Squires L; 311 Study Group. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health. 2009 Jun 9;3(1):17. doi: 10.1186/1753-2000-3-17. PubMed 19508731 ↗
  • Wigal SB, Kollins SH, Childress AC, Adeyi B. Efficacy and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: sex and age effects and effect size across the day. Child Adolesc Psychiatry Ment Health. 2010 Dec 14;4:32. doi: 10.1186/1753-2000-4-32. PubMed 21156071 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2007 to primary completion in Dec 2007, 5 months.

Results were first posted in Jun 2009, 1 year 6 months after primary completion.

Of 66 industry-sponsored phase 3 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 5 months is below that.

Counting every sponsor, half of 80 studies reached it within 14 months; a quarter within 7 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2007
First posted
Jul 12, 2007
StartActual
Jun 13, 2007
Primary completionActual
Dec 5, 2007
CompletionActual
Dec 5, 2007
Results first posted
Jun 5, 2009
Last update
Jun 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00500149
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Jul 12, 2007
Start date
Jun 13, 2007
Primary completion
Dec 5, 2007
Completion
Dec 5, 2007
Results posted
Jun 5, 2009
Last update
Jun 14, 2021

Study contacts

Study Director
study director · Takeda
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion